VCM
ALT icon

Vivaldi Capital Management’s Altimmune ALT Stock Holding History

Vivaldi Capital Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$77.4K – 283
2025
Q2 		$77.4K Hold
20,000
– – 0.01% 293
2025
Q1 		$100K Hold
20,000
– – 0.02% 277
2024
Q4 		$140K Hold
20,000
– – 0.02% 278
2024
Q3 		$123K Hold
20,000
– – 0.04% 222
2024
Q2 		$133K Buy
+20,000
New +$148K 0.04% 224

Other funds holding ALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vivaldi Capital Management's ALT Position: Q3 2025 in Review

Vivaldi Capital Management sold out of Altimmune (ALT) in Q3 2025, closing a stake of 20,000 shares — an estimated $77.4K sold.

Vivaldi Capital Management first reported a position in ALT in Q2 2024 and held it in 5 quarters. The position peaked at $140K in Q4 2024. 158 funds tracked by Wall St. Rank hold ALT as of Q3 2025.

  • Vivaldi Capital Management reported no remaining Altimmune position as of Q3 2025 after selling out during the quarter.
  • Vivaldi Capital Management sold 20,000 Altimmune shares in Q3 2025, an estimated $77.4K.
  • Vivaldi Capital Management first reported a position in Altimmune in Q2 2024 and held it in 5 quarters.
  • Vivaldi Capital Management's Altimmune position peaked at $140K in Q4 2024.
  • 158 funds tracked by Wall St. Rank held Altimmune as of Q3 2025.

Based on Vivaldi Capital Management's 13F filing for Q3 2025, filed 17 Nov 2025.